On Friday, Pfizer Inc. PFE launched topline outcomes from its Part 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), together with Bacillus Calmette-Guérin (BCG) as induction remedy with or with out upkeep for BCG-naïve, high-risk non-muscle invasive bladder most cancers (NMIBC).
The examine met its main endpoint of event-free survival by investigator evaluation, displaying a clinically significant and statistically important enchancment with sasanlimab together with BCG as in comparison with BCG alone.
Additionally Learn: Pfizer And GSK’s RSV Vaccines Security Labels Up to date, FDA Provides Warning For Uncommon Neurological Dysfunction
Every year, round 100,000 people worldwide obtain a prognosis of high-risk NMIBC.
The general security profile of sasanlimab together with BCG was usually in line with the identified profile of BCG and information reported from medical trials with sasanlimab.
The profile of sasanlimab was additionally usually in line with the reported security profile of PD-1 inhibitors.
The corporate plans to submit outcomes for presentation at an upcoming medical congress.
Pfizer intends to debate these information with international well being authorities to help potential regulatory filings. Sasanlimab additionally continues to be investigated together with Pfizer’s antibody-drug conjugate portfolio in superior stable tumors.
Worth Motion: PFE inventory is up 0.28% to $26.94 eventually examine Friday.
Learn Subsequent:
Picture by way of Shutterstock.
Overview Ranking:
Speculative
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
